Prognostic value of FGF23 among patients with end-stage renal disease: A systematic review and meta-analysis

Biomarkers in Medicine

Volumn 10, Issue 5, 2016, Pages 547-556

  Yang, Hongliu ^a   Luo, Han ^a   Tang, Xi ^a   Zeng, Xiaoxi ^a   Yu, Yang ^a   Ma, Liang ^a   Fu, Ping ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

dialysis; end stage renal disease; FGF23; mortality

Indexed keywords

BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR;

AGE DISTRIBUTION; CARDIOVASCULAR MORTALITY; DISEASE MARKER; END STAGE RENAL DISEASE; ETHNICITY; FOLLOW UP; HIGH RISK POPULATION; HUMAN; POPULATION RESEARCH; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; SEX DIFFERENCE; SYSTEMATIC REVIEW; BLOOD; FACTUAL DATABASE; KAPLAN MEIER METHOD; KIDNEY FAILURE, CHRONIC; META ANALYSIS; MORTALITY; ODDS RATIO; PATHOLOGY; PROPORTIONAL HAZARDS MODEL;

BIOMARKERS; DATABASES, FACTUAL; FIBROBLAST GROWTH FACTORS; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; ODDS RATIO; PROPORTIONAL HAZARDS MODELS;

EID: 84969257092     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.16.11     Document Type: Review

References (34)

1. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from kidney disease: Improving Global Outcomes (KDIGO). Kidney Int. 69(11), 1945-1953 (2006).
2. Isakova T, Wahl P, Vargas GS et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 79(12), 1370-1378 (2011).
3. Imanishi Y, Inaba M, Nakatsuka K et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int. 65(5), 1943-1946 (2004).
4. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J. Am. Soc. Nephrol. 16(7), 2205-2215 (2005).
5. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 64(6), 2272-2279 (2003).
6. Shigematsu T, Kazama JJ, Yamashita T et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am. J. Kidney Dis. 44(2), 250-256 (2004).
7. Shimada T, Urakawa I, Isakova T et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J. Clin. Endocrinol. Metab. 95(2), 578-585 (2010).
8. Xiao Y, Luo X, Huang W, Zhang J, Peng C. Fibroblast growth factor 23 and risk of all-cause mortality and cardiovascular events: A meta-analysis of prospective cohort studies. Int. J. Cardiol. 174(3), 824-828 (2014).
9. Hayden JA, Cote P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann. Intern. Med. 144(6), 427-437 (2006).
10. Stroup DF, Berlin JA, Morton SC et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283(15), 2008-2012 (2000).
11. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. www.ohri.ca/programs/clinical-epidemiology/oxford.asp
12. Nowak A, Friedrich B, Artunc F et al. Prognostic value and link to atrial fibrillation of soluble Klotho and FGF23 in hemodialysis patients. PLoS ONE 9(7), e100688 (2014).
13. Hsu HJ, Wu MS. Fibroblast growth factor 23: A possible cause of left ventricular hypertrophy in hemodialysis patients. Am. J. Med. Sci. 337(2), 116-122 (2009).
14. Olauson H, Qureshi AR, Miyamoto T et al. Relation between serum fibroblast growth factor-23 level and mortality in incident dialysis patients: are gender and cardiovascular disease confounding the relationship? Nephrol. Dial. Transplant. 25(9), 3033-3038 (2010).
15. Sugimoto H, Ogawa T, Iwabuchi Y, Otsuka K, Nitta K. Relationship between serum fibroblast growth factor-23 level and mortality in chronic hemodialysis patients. Int. Urol. Nephrol. 46(1), 99-106 (2014).
16. Jean G, Terrat JC, Vanel T et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol. Dial. Transplant. 24(9), 2792-2796 (2009).
17. Holden RM, Beseau D, Booth SL et al. FGF-23 is associated with cardiac troponin T and mortality in hemodialysis patients. Hemodial. Int. 16(1), 53-58 (2012).
18. Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 359(6), 584-592 (2008).
19. Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 121(11), 4393-4408 (2011).
20. Negishi K, Kobayashi M, Ochiai I et al. Association between fibroblast growth factor 23 and left ventricular hypertrophy in maintenance hemodialysis patients. Comparison with B-type natriuretic peptide and cardiac troponin T. Circ. J. 74(12), 2734-2740 (2010).
21. Mehrotra R, Kermah DA, Salusky IB et al. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int. 76(9), 977-983 (2009).
22. Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 72(8), 1004-1013 (2007).
23. Perazella MA, Setaro JF. Renin-angiotensin-aldosterone system: fundamental aspects and clinical implications in renal and cardiovascular disorders. J. Nucl. Cardiol. 10(2), 184-196 (2003).
24. Dai B, David V, Martin A et al. A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS ONE 7(9), e44161 (2012).
25. Hsu JJ, Katz R, Ix JH, De Boer IH, Kestenbaum B, Shlipak MG. Association of fibroblast growth factor-23 with arterial stiffness in the multi-ethnic study of atherosclerosis. Nephrol. Dial. Transplant. 29(11), 2099-2105 (2014).
26. Smith ER, Mcmahon LP, Holt SG. Method-specific differences in plasma fibroblast growth factor 23 measurement using four commercial ELISAs. Clin. Chem. Lab. Med. 51(10), 1971-1981 (2013).
27. System USRD. USRDS 2013 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, MD, USA (2013). www.usrds.org/atlas.aspx
28. Isakova T, Xie H, Barchi-Chung A et al. Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. Clin. J. Am. Soc. Nephrol. 6(11), 2688-2695 (2011).
29. Jia T, Qureshi AR, Brandenburg V et al. Determinants of fibroblast growth factor-23 and parathyroid hormone variability in dialysis patients. Am. J. Nephrol. 37(5), 462-471 (2013).
30. Kestenbaum B, Sachs MC, Hoofnagle AN et al. Fibroblast growth factor-23 and cardiovascular disease in the general population: The multi-ethnic study of atherosclerosis. Circ. Heart Fail. 7(3), 409-417 (2014).
31. Gupta A, Winer K, Econs MJ, Marx SJ, Collins MT. FGF-23 is elevated by chronic hyperphosphatemia. J. Clin. Endocrinol. Metab. 89(9), 4489-4492 (2004).
32. Perwad F, Zhang MY, Tenenhouse HS, Portale AA. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am. J. Physiol. Renal Physiol. 293(5), F1577-F1583 (2007).
33. Nishi H, Nii-Kono T, Nakanishi S et al. Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron. Clin. Pract. 101(2), c94-c99 (2005).
34. Moe SM, Chertow GM, Parfrey PS et al. Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. Circulation 132(1), 27-39 (2015).